APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

RNAi for Therapeutic

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Selected research

Market Analysis & Forecast

Global RNAi for Therapeutic Market Analysis and Forecast 2026-2032

23 December 2025190 pages

Choose your research edition.

Industry ResearchRNAi for Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal RNAi for Therapeutic Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal RNAi for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNAi for Therapeutic Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal RNAi for Therapeutic Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

Read the full market overview

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

Report Includes

This report presents an overview of global market for RNAi for Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of RNAi for Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for RNAi for Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNAi for Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global RNAi for Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for RNAi for Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

RNAi for Therapeutic Segment by Company

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

RNAi for Therapeutic Segment by Type

siRNA

miRNA

shRNA

RNAi for Therapeutic Segment by Application

Cancer

Cardiovascular

HBV

Others

RNAi for Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNAi for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi for Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of RNAi for Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNAi for Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. siRNA Major Player Table 3. miRNA Major Player Table 4. shRNA Major Player Table 5. Global RNAi for Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Major Player Table 7. Cardiovascular Major Player Table 8. HBV Major Player Table 9. Others Major Player Table 10. RNAi for Therapeutic Industry Trends Table 11. RNAi for Therapeutic Industry Drivers Table 12. RNAi for Therapeutic Industry Opportunities and Challenges Table 13. RNAi for Therapeutic Industry Restraints Table 14. Global RNAi for Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global RNAi for Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 16. Global RNAi for Therapeutic Market Share by Region (2021-2026) Table 17. Global RNAi for Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 18. Global RNAi for Therapeutic Market Share by Region (2027-2032) Table 19. Global RNAi for Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 20. Global RNAi for Therapeutic Revenue Market Share by Players (2021-2026) Table 21. Global RNAi for Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global RNAi for Therapeutic Key Players Headquarters & Area Served Table 23. Global RNAi for Therapeutic Players, Product Type & Application Table 24. Global RNAi for Therapeutic Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global RNAi for Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global RNAi for Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 29. Global RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 30. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2026) Table 31. Global RNAi for Therapeutic Revenue Market Share by Type (2027-2032) Table 32. Global RNAi for Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 34. Global RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 35. Global RNAi for Therapeutic Revenue Market Share by Application (2021-2026) Table 36. Global RNAi for Therapeutic Revenue Market Share by Application (2027-2032) Table 37. Alnylam Pharmaceuticals Company Information Table 38. Alnylam Pharmaceuticals Business Overview Table 39. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 41. Alnylam Pharmaceuticals Recent Development Table 42. Arbutus Biopharma (Tekmira) Company Information Table 43. Arbutus Biopharma (Tekmira) Business Overview Table 44. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio Table 46. Arbutus Biopharma (Tekmira) Recent Development Table 47. Arrowhead Company Information Table 48. Arrowhead Business Overview Table 49. Arrowhead RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Arrowhead RNAi for Therapeutic Product Portfolio Table 51. Arrowhead Recent Development Table 52. Dicerna Pharmaceuticals Company Information Table 53. Dicerna Pharmaceuticals Business Overview Table 54. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 56. Dicerna Pharmaceuticals Recent Development Table 57. Mirna Therapeutics Company Information Table 58. Mirna Therapeutics Business Overview Table 59. Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Mirna Therapeutics RNAi for Therapeutic Product Portfolio Table 61. Mirna Therapeutics Recent Development Table 62. Quark Pharmaceuticals Company Information Table 63. Quark Pharmaceuticals Business Overview Table 64. Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 66. Quark Pharmaceuticals Recent Development Table 67. RXi Pharmaceuticals Company Information Table 68. RXi Pharmaceuticals Business Overview Table 69. RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 71. RXi Pharmaceuticals Recent Development Table 72. Silence Therapeutics Company Information Table 73. Silence Therapeutics Business Overview Table 74. Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Silence Therapeutics RNAi for Therapeutic Product Portfolio Table 76. Silence Therapeutics Recent Development Table 77. Benitec Biopharma Company Information Table 78. Benitec Biopharma Business Overview Table 79. Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Benitec Biopharma RNAi for Therapeutic Product Portfolio Table 81. Benitec Biopharma Recent Development Table 82. miRagen Therapeutics Company Information Table 83. miRagen Therapeutics Business Overview Table 84. miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. miRagen Therapeutics RNAi for Therapeutic Product Portfolio Table 86. miRagen Therapeutics Recent Development Table 87. Sylentis Company Information Table 88. Sylentis Business Overview Table 89. Sylentis RNAi for Therapeutic Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Sylentis RNAi for Therapeutic Product Portfolio Table 91. Sylentis Recent Development Table 92. Gradalis Company Information Table 93. Gradalis Business Overview Table 94. Gradalis RNAi for Therapeutic Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Gradalis RNAi for Therapeutic Product Portfolio Table 96. Gradalis Recent Development Table 97. Sirnaomics Company Information Table 98. Sirnaomics Business Overview Table 99. Sirnaomics RNAi for Therapeutic Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Sirnaomics RNAi for Therapeutic Product Portfolio Table 101. Sirnaomics Recent Development Table 102. Silenseed Company Information Table 103. Silenseed Business Overview Table 104. Silenseed RNAi for Therapeutic Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Silenseed RNAi for Therapeutic Product Portfolio Table 106. Silenseed Recent Development Table 107. North America RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 108. North America RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 109. North America RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 110. North America RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 111. North America RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America RNAi for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 113. North America RNAi for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe RNAi for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe RNAi for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 121. China RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 122. China RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 123. China RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 124. China RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia RNAi for Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia RNAi for Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia RNAi for Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA RNAi for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA RNAi for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA RNAi for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA RNAi for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA RNAi for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA RNAi for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. RNAi for Therapeutic Image Figure 2. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNAi for Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. siRNA Image Figure 5. miRNA Image Figure 6. shRNA Image Figure 7. Global RNAi for Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global RNAi for Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Image Figure 10. Cardiovascular Image Figure 11. HBV Image Figure 12. Others Image Figure 13. Global RNAi for Therapeutic Market Size (US$ Million) & (2021-2032) Figure 14. Global RNAi for Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global RNAi for Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global RNAi for Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global RNAi for Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global RNAi for Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2032) Figure 21. Global RNAi for Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global RNAi for Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global RNAi for Therapeutic Revenue Market Share by Application (2021-2032) Figure 24. North America RNAi for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America RNAi for Therapeutic Revenue Share by Type (2021-2032) Figure 26. North America RNAi for Therapeutic Revenue Share by Application (2021-2032) Figure 27. North America RNAi for Therapeutic Revenue Share by Country (2021-2032) Figure 28. United States RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe RNAi for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe RNAi for Therapeutic Revenue Share by Type (2021-2032) Figure 33. Europe RNAi for Therapeutic Revenue Share by Application (2021-2032) Figure 34. Europe RNAi for Therapeutic Revenue Share by Country (2021-2032) Figure 35. Germany RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China RNAi for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China RNAi for Therapeutic Revenue Share by Type (2021-2032) Figure 45. China RNAi for Therapeutic Revenue Share by Application (2021-2032) Figure 46. Asia RNAi for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia RNAi for Therapeutic Revenue Share by Type (2021-2032) Figure 48. Asia RNAi for Therapeutic Revenue Share by Application (2021-2032) Figure 49. Asia RNAi for Therapeutic Revenue Share by Region (2021-2032) Figure 50. Japan RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA RNAi for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA RNAi for Therapeutic Revenue Share by Type (2021-2032) Figure 58. SAMEA RNAi for Therapeutic Revenue Share by Application (2021-2032) Figure 59. SAMEA RNAi for Therapeutic Revenue Share by Country (2021-2032) Figure 60. Brazil RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt RNAi for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • siRNA
  • miRNA
  • shRNA
Applications
  • Cancer
  • Cardiovascular
  • HBV
  • Others
Companies covered
  • Alnylam Pharmaceuticals
  • Arbutus Biopharma (Tekmira)
  • Arrowhead
  • Dicerna Pharmaceuticals
  • Mirna Therapeutics
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • Silence Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 RNAi for Therapeutic Market by Type
  3. 1.2.1 Global RNAi for Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 siRNA
  5. 1.2.3 miRNA
  6. 1.2.4 shRNA
  7. 1.3 RNAi for Therapeutic Market by Application
  8. 1.3.1 Global RNAi for Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Cardiovascular
  11. 1.3.4 HBV
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 RNAi for Therapeutic Market Dynamics
  1. 2.1 RNAi for Therapeutic Industry Trends
  2. 2.2 RNAi for Therapeutic Industry Drivers
  3. 2.3 RNAi for Therapeutic Industry Opportunities and Challenges
  4. 2.4 RNAi for Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global RNAi for Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global RNAi for Therapeutic Growth Trends by Region
  3. 3.2.1 Global RNAi for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global RNAi for Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global RNAi for Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global RNAi for Therapeutic Revenue by Players
  2. 4.1.1 Global RNAi for Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global RNAi for Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global RNAi for Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global RNAi for Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global RNAi for Therapeutic Players, Product Type & Application
  8. 4.5 Global RNAi for Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global RNAi for Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 RNAi for Therapeutic Tier 1, Tier 2, and Tier 3
5 RNAi for Therapeutic Market Size by Type
  1. 5.1 Global RNAi for Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global RNAi for Therapeutic Revenue Market Share by Type (2021-2032)
6 RNAi for Therapeutic Market Size by Application
  1. 6.1 Global RNAi for Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global RNAi for Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global RNAi for Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alnylam Pharmaceuticals
  2. 7.1.1 Alnylam Pharmaceuticals Company Information
  3. 7.1.2 Alnylam Pharmaceuticals Business Overview
  4. 7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio
  6. 7.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 7.2 Arbutus Biopharma (Tekmira)
  8. 7.2.1 Arbutus Biopharma (Tekmira) Company Information
  9. 7.2.2 Arbutus Biopharma (Tekmira) Business Overview
  10. 7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio
  12. 7.2.5 Arbutus Biopharma (Tekmira) Recent Developments
  13. 7.3 Arrowhead
  14. 7.3.1 Arrowhead Company Information
  15. 7.3.2 Arrowhead Business Overview
  16. 7.3.3 Arrowhead RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Arrowhead RNAi for Therapeutic Product Portfolio
  18. 7.3.5 Arrowhead Recent Developments
  19. 7.4 Dicerna Pharmaceuticals
  20. 7.4.1 Dicerna Pharmaceuticals Company Information
  21. 7.4.2 Dicerna Pharmaceuticals Business Overview
  22. 7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio
  24. 7.4.5 Dicerna Pharmaceuticals Recent Developments
  25. 7.5 Mirna Therapeutics
  26. 7.5.1 Mirna Therapeutics Company Information
  27. 7.5.2 Mirna Therapeutics Business Overview
  28. 7.5.3 Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mirna Therapeutics RNAi for Therapeutic Product Portfolio
  30. 7.5.5 Mirna Therapeutics Recent Developments
  31. 7.6 Quark Pharmaceuticals
  32. 7.6.1 Quark Pharmaceuticals Company Information
  33. 7.6.2 Quark Pharmaceuticals Business Overview
  34. 7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio
  36. 7.6.5 Quark Pharmaceuticals Recent Developments
  37. 7.7 RXi Pharmaceuticals
  38. 7.7.1 RXi Pharmaceuticals Company Information
  39. 7.7.2 RXi Pharmaceuticals Business Overview
  40. 7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio
  42. 7.7.5 RXi Pharmaceuticals Recent Developments
  43. 7.8 Silence Therapeutics
  44. 7.8.1 Silence Therapeutics Company Information
  45. 7.8.2 Silence Therapeutics Business Overview
  46. 7.8.3 Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Silence Therapeutics RNAi for Therapeutic Product Portfolio
  48. 7.8.5 Silence Therapeutics Recent Developments
  49. 7.9 Benitec Biopharma
  50. 7.9.1 Benitec Biopharma Company Information
  51. 7.9.2 Benitec Biopharma Business Overview
  52. 7.9.3 Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Benitec Biopharma RNAi for Therapeutic Product Portfolio
  54. 7.9.5 Benitec Biopharma Recent Developments
  55. 7.10 miRagen Therapeutics
  56. 7.10.1 miRagen Therapeutics Company Information
  57. 7.10.2 miRagen Therapeutics Business Overview
  58. 7.10.3 miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 miRagen Therapeutics RNAi for Therapeutic Product Portfolio
  60. 7.10.5 miRagen Therapeutics Recent Developments
  61. 7.11 Sylentis
  62. 7.11.1 Sylentis Company Information
  63. 7.11.2 Sylentis Business Overview
  64. 7.11.3 Sylentis RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sylentis RNAi for Therapeutic Product Portfolio
  66. 7.11.5 Sylentis Recent Developments
  67. 7.12 Gradalis
  68. 7.12.1 Gradalis Company Information
  69. 7.12.2 Gradalis Business Overview
  70. 7.12.3 Gradalis RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Gradalis RNAi for Therapeutic Product Portfolio
  72. 7.12.5 Gradalis Recent Developments
  73. 7.13 Sirnaomics
  74. 7.13.1 Sirnaomics Company Information
  75. 7.13.2 Sirnaomics Business Overview
  76. 7.13.3 Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Sirnaomics RNAi for Therapeutic Product Portfolio
  78. 7.13.5 Sirnaomics Recent Developments
  79. 7.14 Silenseed
  80. 7.14.1 Silenseed Company Information
  81. 7.14.2 Silenseed Business Overview
  82. 7.14.3 Silenseed RNAi for Therapeutic Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Silenseed RNAi for Therapeutic Product Portfolio
  84. 7.14.5 Silenseed Recent Developments
8 North America
  1. 8.1 North America RNAi for Therapeutic Revenue (2021-2032)
  2. 8.2 North America RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America RNAi for Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America RNAi for Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America RNAi for Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America RNAi for Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America RNAi for Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America RNAi for Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America RNAi for Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America RNAi for Therapeutic Revenue by Country
  11. 8.6.1 North America RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America RNAi for Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America RNAi for Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe RNAi for Therapeutic Revenue (2021-2032)
  2. 9.2 Europe RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe RNAi for Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe RNAi for Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe RNAi for Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe RNAi for Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe RNAi for Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe RNAi for Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe RNAi for Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe RNAi for Therapeutic Revenue by Country
  11. 9.6.1 Europe RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe RNAi for Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe RNAi for Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China RNAi for Therapeutic Revenue (2021-2032)
  2. 10.2 China RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China RNAi for Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China RNAi for Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China RNAi for Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China RNAi for Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China RNAi for Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China RNAi for Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China RNAi for Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia RNAi for Therapeutic Revenue (2021-2032)
  2. 11.2 Asia RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia RNAi for Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia RNAi for Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia RNAi for Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia RNAi for Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia RNAi for Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia RNAi for Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia RNAi for Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia RNAi for Therapeutic Revenue by Country
  11. 11.6.1 Asia RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia RNAi for Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia RNAi for Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA RNAi for Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA RNAi for Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA RNAi for Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA RNAi for Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA RNAi for Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA RNAi for Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA RNAi for Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA RNAi for Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA RNAi for Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA RNAi for Therapeutic Revenue by Country
  11. 12.6.1 SAMEA RNAi for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA RNAi for Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA RNAi for Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst